Current Clinical Trials

Current Clinical Trials

Cancer Studies:

SCUSF-0806 : "Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)"

The primary objective of this study is to determine if administration of lisinopril or Coreg CR(r), compared to placebo, will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in patients receiving adjuvant, or neoadjuvant, therapy for HER2 positive breast cancer.

Dr. Luke Dreisbach is the Principal Investigator. All Eisenhower Medical Center Medical Oncologists may enroll their patients to this study. Contact Stephanie Farrell at (760) 674-3644 or sfarrell@emc.org for more information


"NSABP-B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Normal Invasive Breast Cancer"

This study will enroll patients with early stage breast cancer that has been removed by surgery. The main purpose of this study is to learn if adding a targeted therapy, trastuzumab (Herceptin®), to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning.

Dr. Luke Dreisbach is the Principal Investigator. All Eisenhower Medical Center Medical Oncologists may enroll their patients to this study. Contact Stephanie Farrell at (760) 674-3644 or sfarrell@emc.org for more information.


"E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma"

This study will enroll patients with high-risk skin cancer (melanoma) which, although it has been successfully treated with surgery, has a high probability of coming back. The purpose of this study is to compare the effects, of ipilimumab with interferon alfa-2b in treating melanoma

Dr. Henry Tsai is the Principal Investigator. All Eisenhower Medical Center Medical Oncologists may enroll their patients to this study. Contact Stephanie Farrell at (760) 674-3644 or sfarrell@emc.org for more information.


"ECOG E1505: Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patient with Completely resected Stage IB-IIIA Non-small Cell Lung Cancer"

This study will enroll patients who have non-small cell lung cancer, which has been surgically removed. The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer.

Dr. Luke Dreisbach is the Principal Investigator. All Eisenhower Medical Center Medical Oncologists may enroll their patients to this study. Contact Stephanie Farrell at (760) 674-3644 or sfarrell@emc.org for more information.


"International Early Lung Cancer Program (I-ELCAP) Eisenhower Lucy Curci Cancer Center Detection Program Using Computerized Tomography" -

This study will enroll patients who are at least 50 years old, have a life expectancy of 10 years or greater and are either a current or former smoker.

The purpose of this research is to study how well annual computed tomography (CT) screening of the lungs can detect early lung cancer, chronic obstructive pulmonary disease (emphysema or chronic bronchitis) and cardiovascular disease and to relate these evaluations to risk factors for lung cancer and long-term survival and the other findings seen on CT of the chest

Dr. Davood Vafai is the Principal Investigator. Contact Keith Smith at (760) 674-8034 for more information.


"Eisenhower Lucy Curci Cancer Center Flight Attendant Medical Research Institute (FAMRI) - International Early Lung Cancer Action Program (I-ELCAP) Protocol"

This research is being done in order to develop appropriate clinical programs for never-smokers who have been exposed to secondhand smoke. The study will enroll people who are 40 years or older and have not smoked more than 100 cigarettes in their lifetime. The purpose of this study is to determine the likelihood of specific pulmonary diseases, including chronic obstructive pulmonary disease (COPD), emphysema, lung cancer cardiac disease, and other diseases in never smokers exposed to secondhand smoke and to relate this likelihood to exposure to smoke and other related factors and the likely outcome of these diseases based on a single computed tomographic (CT) examination of the lungs.

Dr. Davood Vafai is the Principal Investigator. Contact Keith Smith at (760) 674-8034 for more information.


"NSABP P5: Phase III Randomized Study of Adjuvant Rosuvastatin in Patients with Resected Stage I or II Colon Cancer.

This study will enroll patients who have colon cancer, which has been surgically removed. The main purpose of this study is to find out whether or not rosuvastatin (also called Crestor®) is able to prevent colon polyps and colorectal cancer from occurring in patients who have already had a colon cancer removed by surgery.

Dr. Luke Dreisbach is the Principal Investigator. All Eisenhower Medical Center Medical Oncologists may enroll their patients to this study. Contact Keith Smith at (760) 674-8034 for more information.


"S0931 EVEREST: EVErolimus for Renal Cancer Ensuring Surgical Therapy, A Phase III Study "

This study will enroll patients who have cancer of the kidney, which has been surgically removed. The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning.

Dr. Henry Tsai is the Principal Investigator. All Eisenhower Medical Center Medical Oncologists may enroll their patients to this study. Contact Keith Smith at (760) 674-8034 for more information.


Cardiac Studies:

"Echocardiography Guided Cardiac Resynchronization Therapy Clinical Investigation - EchoCRT"

This study will enroll patients who require an implantable cardioverter defibrillator (ICD) because they have had, or are at risk of having, fast, irregular heart rhythms in the lower chambers of their heart. This study will try to determine if Cardiac Resynchronization Therapy (CRT) can prevent death or reduce Heart Failure hospitalizations for patients who have dyssynchrony on an Echocardiogram, but don’t have the delayed pulse conduction on an ECG.

Dr. Leon Feldman is the Principal Investigator. Contact Sharon Kunic at (760) 346-0642 ext. 263 for more information.


"Accent MRI"

This study will enroll patients who qualify for a pacemaker and are not contraindicated for undergoing an MRI scan. Safety and efficacy of the implanted Accent MRI system by St. Jude Medical will be evaluated in and out of the MRI environment.

Dr. Andrew Rubin is the Principal Investigator. Contact Sharon Kunic at (760) 346-0642 ext.263 for more information.


"INGEVITY"

This study will enroll patients who have not had a pacemaker implant before and now qualify for a pacemaker and are not contraindicated for undergoing an MRI Scan. Safety, performance and effectiveness of the Boston Scientific INGEVITY System will be evaluated.

Dr. Andrew Rubin is the Principal Investigator. Contact Sharon Kunic at (760) 346-0642 ext.263 for more information.


Neurology Studies:

"POINT (Platelet-Oriented Inhibition in New TIA or Minor Stroke"

This study will enroll patients who have had a TIA or a minor stroke within 12 hours. This study examines whether the combination of aspirin and clopidogrel (also known as Plavix) increases the effectiveness in reducing the risk of stroke, heart attacks and other complications in patients who have just had a transient ischemic attack or a minor stroke. The study will also compare the risks of the combination with the risks from aspirin alone.

Dr. Bishoy Labib is the Principal Investigator. Contact K. Kamel at (760) 779-1177 for more information.


Orthopedic Studies:

"A Randomized, Prospective, Comparative Study of Acupuncture and Post-Operative Pain Management with Shoulder Arthroplasty"

This study will enroll patients who are undergoing shoulder arthroplasty. The purpose of the study is to compare the effect of acupuncture on the perception of post-operative pain, the requirement for post operative pain medication, and incidence of post operative nausea, ileus (bowel obstruction), and confusion in patients undergoing shoulder arthroplasty

Dr. Patrick St. Pierre is the Principal Investigator. Contact Charlie Cyr at (760) 766-2540 for more information.


"The Investigational Plan for the Evaluation of the ACADIA™ Facet Replacement System (Pivotal IDE Trial)"

This study will enroll patients who have Spinal Stenosis and a degenerative facet joint in their lower spine.The purpose of this research study is to evaluate the Acadia™ Facet Replacement System (a facet implant/study device) that has been designed to replace diseased facet joints.

Dr. A. David Tahernia, MD is the Principal Investigator. Contact Charlie Cyr at (760) 766-2540 for more information.


Infectious Disease Studies:

"A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections"

This study will enroll patients who have a fungal infection that is probably caused by Candida. The study medication that will be tested has strong activity against fungi including Candida. The main purpose of this study is to determine the safety and effectiveness of isavuconazole compared to established standard treatment (caspofungin and voriconazole). Isavuconazole is an investigational antifungal medication which is not approved yet for the treatment of serious fungal infections.

Dr. Michael Somero is the Principal Investigator. Contact Kathy Colgin at (760) 346-3430 for more information.


"A Randomized, Double-Blinded, Active-Controlled Study of an oral

Daptomycin-derivative vs. oral Vancomycin in Patients with Clostridium difficile Associated Diarrhea."

This Phase III study is enrolling in-patients as well as out-patients for a 10 day treatment period.

Dr. Massoud Dezfuli is the Principal Investigator. Please call Daniel Rangel for more information at (760) 834-7983 or (760) 660-3285 [cell].


HIV Studies:

"A study to evaluate Diabetic Retinopathy in HIV subjects treated with EGRIFTA® "

This is a prospective, randomized, placebo-controlled, double-blind clinical trial to

Evaluate whether EGRIFTA® (tesamorelin for injection), 2 mg once daily SC, increases the risk of development or progression of diabetic retinopathy when administered to HIV-infected subjects with abdominal lipohypertrophy and concomitant diabetes.

Dr. Richard Loftus is the Principal Investigator. Dr. Bruce Bornfleth is the Sub-Investigator. Please call Erik Hernandez at (760) 902-9615 for more information.


A Switch Trial: "Study of Atazanavir/Ritonavir (Reyataz®/Norvir®) plus Raltegravir(Isentress)and Atazanavir/Ritonavir (Reyataz®/Norvir®) plus Tenofovir/Emtricitabine (Truvada®) in Patients with HIV-1 Infection"

This is an Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on their Present Treatment Regimen

Dr. Richard Loftus is the Principal Investigator. Dr. Bruce Bornfleth is the Sub-Investigator. Please call Erik Hernandez at (760) 902-9615 for more information.


Pulmonology

GlaxoSmithKline HZC113782: "A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25 mcg with Placebo on Survival in Subjects with Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease"

This is a Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease.

Dr. Hassan Bencheqroun is the Principal Investigator. Please call Daniel Rangel at (760) 834-7983 or Edna Wood at (760) 834-3564 for more information.


CCBot/2.0 (http://commoncrawl.org/faq/)